Nyan Latt, MD
Transplant Hepatology · Camden, NJNPI 1598086290
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 119 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by Gilead at 27.3% of the total. 2025 is the largest year on record at $604, 5.2 times the $115 reported in 2021.
Across 119 payments — averaging $19.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$643
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$598
- AbbVie$220
- Haemonetics Corporation$218
- Ipsen Biopharmaceuticals, Inc$155
- Ortho Dermatologics, A Division Of Bausch Health US, LLC$118
- plus $406 from 13 others
Across 92 payments — averaging $1247.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bausch Health US, LLC$98K
- Gilead$17K
What the payments were for
- Food & beverage$2,359100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 33 | $643 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 39 | $598 |
| AbbVie | 16 | $220 |
| Haemonetics Corporation | 3 | $218 |
| Ipsen Biopharmaceuticals, Inc | 7 | $155 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $118 |
| Mallinckrodt Hospital Products Inc. | 1 | $107 |
| Intercept Pharmaceuticals, Inc. | 3 | $52 |
| Dynavax Technologies Corporation | 4 | $45 |
| Sobi, Inc | 2 | $31 |
| Madrigal Pharmaceuticals | 2 | $31 |
| Lemaitre Vascular, Inc. | 1 | $26 |
| Eisai Inc. | 1 | $21 |
| Albireo Pharma, Inc. | 1 | $19 |
| Orphalan Inc | 1 | $18 |
| Perspectum Diagnostics Ltd | 1 | $17 |
| AstraZeneca | 1 | $14 |
| Vifor Pharma, Inc. | 1 | $13 |
| Alnylam Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few transplant hepatology providers in New Jerseyto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 102 | $337,856 |
| EpclusaSofosbuvir/Velpatasvir | 13 | $316,027 |
| MavyretGlecaprevir/Pibrentasvir | 12 | $154,454 |
| RezdiffraResmetirom | 18 | $71,193 |
| Ursodiol | 73 | $53,014 |
| EliquisApixaban | 34 | $24,735 |
| VemlidyTenofovir Alafenamide | 14 | $22,420 |
| Tacrolimus | 143 | $10,894 |
| Mycophenolic AcidMycophenolate Sodium | 25 | $5,494 |
| Entecavir | 28 | $3,028 |
| Budesonide EcBudesonide | 11 | $2,018 |
| Lactulose | 68 | $1,808 |
| Spironolactone | 136 | $1,450 |
| Rosuvastatin Calcium | 82 | $1,375 |
| Carvedilol | 139 | $816 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadEpclusa, Vemlidy | $643 | $338,44627 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $598 | $337,856102 claims |
| AbbVieMavyret | $220 | $154,45412 claims |
| Madrigal PharmaceuticalsRezdiffra | $31 | $71,19318 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few transplant hepatology providers in New Jerseyon file to place this against a meaningful peer group, so we don't.
Other transplant hepatology in Camden
- Santiago MunozToms River$877K
- Paul GaglioNewark$304K
- Hisham ElgenaidiCherry Hill$206K
- Ashraf MalekCherry Hill$119K
- Simona RossiCherry Hill$116K
- Sandeep BhargavaHaddon Heights$8K
- Daria YuninaSummit$4K
- Zaid TafeshNewark$110
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.